Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.

Paz-Ares, L; Chen, Y; Reinmuth, N; Hotta, K; Trukhin, D; Statsenko, G; Hochmair, M; Özgüroğlu, MUSTAFA; Ji, J; Garassino, M; Voitko, O; Poltoratskiy, A; Musso, E; Havel, L; Bondarenko, I; Losonczy, G; Conev, N; Mann, H; Dalvi, T; Jiang, H; Goldman, J

doi:10.1016/j.esmoop.2022.100408

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.

Paz-Ares L., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., ...Daha Fazla

ESMO open, cilt.7, sa.2, ss.100408, 2022 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 7 Sayı: 2
Basım Tarihi: 2022
Doi Numarası: 10.1016/j.esmoop.2022.100408
Dergi Adı: ESMO open
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
Sayfa Sayıları: ss.100408
Anahtar Kelimeler: durvalumab, tremelimumab, extensive-stage SCLC, CASPIAN, overall survival, EXPRESSION, OUTCOMES
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab plus tremelimumab plus EP numerically improved OS versus EP, but did not reach statistical significance. Here we report updated OS in censored patients after median follow-up of >3 years.